Abstract A076: Evaluating cardiometabolic and oncologic risk among Puerto Rican men with prostate cancer
Authors: Carlos J. Diaz Osterman, Nicole Torres Muriel, Shannalee R. Martinez, Noemi Santiago, Brenda L. Rodriguez Ruiz, Geoffrey Rodriguez, Eric Rosa, Ana M. Escalona Cruz, Ralph Krumhansl, Julie Dutil, Kosj Yamoah, Jong Y. Park, William Roman Torreguitart
Journal: Cancer Research (2023)

Abstract Background. Cardiovascular and metabolic disorders are significant contributors to mortality among men with prostate cancer. However, no evidence is yet available for the role of cardiometabolic comorbidities in the tumor risk stratification or clinical management of men with prostate cancer. Like African American men, Puerto Rican men have a higher risk of developing and dying from prostate cancer than other racial/ethnic groups in the United States. As cardiovascular and metabolic risk factors are highly prevalent in Puerto Rico, we proposed to investigate coordinated risk evaluation of cardiometabolic and oncologic risk in this population. We hypothesized that a subset of cardiometabolic risk factors consistently correlate with clinically defined aggressive disease. Methods. The Puerto Rico Urology Group (PRUG) is the largest group urology practice in Puerto Rico. It currently consists of eight urologists serving the Western, Southern, Central, and Metropolitan regions of Puerto Rico including the island municipalities of Vieques and Culebra. A cohort (n=401) of patients treated to between 2018 and 2022 by the PRUG have been identified for analysis in this study, of which n=30 have been analyzed to date. Clinical data were extracted from consented patients’ medical records with approval by the Ponce Research Institute Institutional Review Board (IRB approval no. 2210121134). Post-surgical cancer of the prostate risk assessment (CAPRA-S) were used to stratify tumors and cardiovascular and metabolic risk factors were evaluated across tumor risk strata. Results. Of the 14 patients with intermediate or high risk, all had a body mass index over 26 compared to 7/16 patients with low-risk tumors (p=0.0009). Among patients with intermediate/high risk, 12/14 had high blood pressure compared to 8/16 patients with low-risk tumors (p=0.0577, RR=3.0). Hyperlipidemia was present in 5/14 patients with intermediate/high risk and 1/16 patients with low-risk tumors (p=0.0725, RR=2.22). Hypercholesterolemia was detected in 3/14 intermediate/high risk and in 6/16 low risk tumors (p=0.4397, RR=0.63). Other cardiometabolic risk factors including diabetes with complications and smoking status did not differ between cancer risk groups. Discussion. The Puerto Rican population represents the second largest Hispanic/Latino subgroup in the United States and has disproportionately high rates of prostate cancer and cardiometabolic comorbidity. Our preliminary findings indicate that the coordinated evaluation of cancer risk in the context of cardiovascular and metabolic risk factors may provide additional insights for risk stratification for patients with prostate cancer from populations with high prevalence of these chronic diseases. Although the study was limited by sample size, our findings provide insights for ongoing studies to evaluate large, multi-institutional cohorts and identify molecular indicators of cardiometabolic risk predictive of prostate cancer aggressiveness among diverse populations. Citation Format: Carlos J. Diaz Osterman, Nicole Torres Muriel, Shannalee R. Martinez, Noemi Santiago, Brenda L. Rodriguez Ruiz, Geoffrey Rodriguez, Eric Rosa, Ana M. Escalona Cruz, Ralph Krumhansl, Julie Dutil, Kosj Yamoah, Jong Y. Park, William Roman Torreguitart. Evaluating cardiometabolic and oncologic risk among Puerto Rican men with prostate cancer [abstract]. In: Proceedings of the AACR Special Conference: Advances in Prostate Cancer Research; 2023 Mar 15-18; Denver, Colorado. Philadelphia (PA): AACR; Cancer Res 2023;83(11 Suppl):Abstract nr A076.